Archive for the ‘News’ Category

Avail Clinical Research Announces Tobacco Consumers Research Studies in DeLand, Florida

Wednesday, March 10th, 2010

DeLand, Florida— March 10, 2010 — Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, Florida, announces the launch of several tobacco consumers clinical trials to test investigational treatment options for those who use SNUS, chew, or dip and have no intention of quitting. “We are very pleased to begin the systemic evaluation of our research studies regarding tobacco consumers and their strong desires to us these types of tobacco products,” said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe that these research studies will build significantly on the data generated by other studies conducted on tobacco consumers.” Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The research studies will enroll those who are current tobacco users, and in order to participate in the studies volunteers must be users of SNUS (pronounced – ’snooze’), chew, or dip. In addition they should have the no desire to quit using either of these products.

Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our clinical trials, contact Avail Clinical Research at 386.310.1334, or at www.AvailClinical.com.

Avail Clinical Research Announces Psoriasis Research Studies in DeLand, Florida

Monday, March 8th, 2010

DeLand, Florida— March 8, 2010 — Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, Florida, announces the launch of several psoriasis clinical trials to test investigational treatment options for those already diagnosed with psoriasis. “We are very pleased to begin the systemic evaluation of our research studies to help find a viable investigational treatment solution to those suffering from psoriasis,” said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe that these research studies will build significantly on the data generated by other studies conducted on investigational treatment options for psoriasis.” Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The research studies will enroll those already diagnosed with psoriasis, which includes symptoms red patches with silvery scales, dry cracked skin that may bleed, thickened or ridged nails, and swollen and stiff joints. In order to participate in the studies volunteers must be diagnosed with psoriasis. Avail Clinical Research will not take volunteers who:

• have any evidence or treatment of malignancy within the previous 5 years,
• have a history of alcohol or substance abuse within the previous 5 years,
• have used an investigatory drug or participated in an investigatory study within 30 days of the screening,
• are pregnant, or
• are breast-feeding.

Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our clinical trials, contact Avail Clinical Research at 386.310.1334, or at www.AvailClinical.com.

Avail Clinical Research Announces Vaccines Research Studies in DeLand, Florida

Friday, March 5th, 2010

DeLand, Florida— March 5, 2010 — Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, Florida, announces the launch of several vaccines clinical trials to test investigational treatment options for those already diagnosed with a specific diagnosis. “We are very pleased to begin the systemic evaluation of our vaccines research studies to help find a viable investigational treatment solution to those suffering from a specific diagnosis,” said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe that these research studies will build significantly on the data generated by other studies conducted on investigational treatment options for your specific diagnosis.” Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The vaccines research studies will enroll those already diagnosed with a specific diagnosis, which includes a multitude of symptoms from abdominal pain and bloating to chronic pain and other physical ailments. In order to participate in the studies volunteers must be diagnosed with a specific diagnosis. Avail Clinical Research will not take volunteers who:

• have any evidence or treatment of malignancy within the previous 5 years,
• have a history of alcohol or substance abuse within the previous 5 years,
• have used an investigatory drug or participated in an investigatory study within 30 days of the screening,
• are pregnant, or
• are breast-feeding.

Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our clinical trials, contact Avail Clinical Research at 386.310.1334, or at www.AvailClinical.com.

Avail Clinical Research Announces Smoking Cessation Research Studies in DeLand, Florida

Thursday, March 4th, 2010

DeLand, Florida— March 4, 2010 — Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, Florida, announces the launch of several smoking cessation clinical trials to test investigational treatment options for those already diagnosed with a nicotine addiction. “We are very pleased to begin the systemic evaluation of our smoking cessation research studies to help find a viable investigational treatment solution to those suffering from nicotine addiction,” said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe that these research studies will build significantly on the data generated by other studies conducted on investigational treatment options for nicotine addiction.” Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The smoking cessation research studies will enroll those already diagnosed with nicotine addiction, which includes symptoms like intense cravings for a cigarette when stressed, and anxiety, agitation, headaches, and nausea when without a cigarette for more than thirty minutes. In order to participate in the studies volunteers must be diagnosed with nicotine addiction. Avail Clinical Research will not take volunteers who:

• have any evidence or treatment of malignancy within the previous 5 years,
• have a history of alcohol or substance abuse within the previous 5 years,
• have used an investigatory drug or participated in an investigatory study within 30 days of the screening,
• are pregnant, or
• are breast-feeding.

Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our clinical trials, contact Avail Clinical Research at 386.310.1334, or at www.AvailClinical.com.

Avail Clinical Research Announces Rheumatoid Arthritis Research Studies in DeLand, Florida

Wednesday, March 3rd, 2010

DeLand, Florida— March 3, 2010 — Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, FL, announces the launch of several rheumatoid arthritis clinical trials to test investigational treatment options for those already diagnosed with rheumatoid arthritis. “We are very pleased to begin the systemic evaluation of our research studies to help find a viable investigational treatment solution to those suffering from rheumatoid arthritis,” said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe that these research studies will build significantly on the data generated by other studies conducted on investigational treatment options for rheumatoid arthritis.” Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The research studies will enroll those already diagnosed with rheumatoid arthritis, which includes symptoms like joint pain, tenderness and swelling, firm bumps of tissue under the skin on your arms, fatigue, and morning stiffness that lasts for hours. In order to participate in the studies volunteers must be diagnosed with rheumatoid arthritis. Avail Clinical Research will not take volunteers who:

• have any evidence or treatment of malignancy within the previous 5 years,
• have a history of alcohol or substance abuse within the previous 5 years,
• have used an investigatory drug or participated in an investigatory study within 30 days of the screening,
• are pregnant, or
• are breast-feeding.

Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our clinical trials, contact Avail Clinical Research at 386.310.1334, or at www.AvailClinical.com.

Avail Clinical Research Announces Restless Leg Syndrome Research Studies in DeLand, Florida

Tuesday, March 2nd, 2010

DeLand, Florida— March 2, 2010 — Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, Florida, announces the launch of several restless leg syndrome clinical trials to test investigational treatment options for those already diagnosed with restless leg syndrome (RLS). “We are very pleased to begin the systemic evaluation of our research studies to help find a viable investigational treatment solution to those suffering from restless leg syndrome,” said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe that these research studies will build significantly on the data generated by other studies conducted on investigational treatment options for RLS.” Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The research studies will enroll those already diagnosed with restless leg syndrome, which includes symptoms in your calves, thighs, and feet that are often expressed as crawling, tingling, cramping, pulling, painful, tugging, gnawing and burning. They typically begin after laying down or sitting for an extended period and lessens as you move. In order to participate in the studies volunteers must be diagnosed with restless leg syndrome. Avail Clinical Research will not take volunteers who:

• have any evidence or treatment of malignancy within the previous 5 years,
• have a history of alcohol or substance abuse within the previous 5 years,
• have used an investigatory drug or participated in an investigatory study within 30 days of the screening,
• are pregnant, or
• are breast-feeding.

Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our clinical trials, contact Avail Clinical Research at 386.310.1334, or at www.AvailClinical.com.

Avail Clinical Research Announces Overactive Bladder Research Studies in DeLand, Florida

Monday, March 1st, 2010

DeLand, Florida— March 1 2010 — Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, Florida, announces the launch of several overactive bladder clinical trials to test investigational treatment options for those already diagnosed with an overactive bladder. “We are very pleased to begin the systemic evaluation of our research studies to help find a viable investigational treatment solution to those suffering from an overactive bladder,” said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe that these research studies will build significantly on the data generated by other studies conducted on investigational treatment options for overactive bladder.” Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The research studies will enroll those already diagnosed with an overactive bladder, which includes symptoms like strong and sudden urges to urinate, involuntary loss of urine immediately following the urgent need to urinate, urinate eight or more times in 24 hours, and awaken two or more times a night to urinate. In order to participate in the studies volunteers must be diagnosed with an overactive bladder. Avail Clinical Research will not take volunteers who:

• have any evidence or treatment of malignancy within the previous 5 years,
• have a history of alcohol or substance abuse within the previous 5 years,
• have used an investigatory drug or participated in an investigatory study within 30 days of the screening,
• are pregnant, or
• are breast-feeding.

Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our clinical trials, contact Avail Clinical Research at 386.310.1334, or at www.AvailClinical.com.

Avail Clinical Research Announces Osteoarthritis Research Studies in DeLand, Florida

Friday, February 26th, 2010

DeLand, Florida— February 26, 2010 — Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, Florida, announces the launch of several osteoarthritis clinical trials to test investigational treatment options for those already diagnosed with osteoarthritis (OA). “We are very pleased to begin the systemic evaluation of our research studies to help find a viable investigational treatment solution to those suffering from osteoarthritis,” said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe that these research studies will build significantly on the data generated by other studies conducted on investigational treatment options for O.A.” Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The research studies will enroll those already diagnosed with osteoarthritis, which includes symptoms like pain in the hands, hips, knees or feet, stiffness for more than an hour, tenderness and occasional swelling, and joint deformity. In order to participate in the studies volunteers must be diagnosed with osteoarthritis. Avail Clinical Research will not take volunteers who:

• have any evidence or treatment of malignancy within the previous 5 years,
• have a history of alcohol or substance abuse within the previous 5 years,
• have used an investigatory drug or participated in an investigatory study within 30 days of the screening,
• are pregnant, or
• are breast-feeding.

Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our our clinical trials, contact Avail Clinical Research at 386.310.1334, or at www.AvailClinical.com.

Avail Clinical Research Announces Obesity and Weight Loss Research Studies in DeLand, Florida

Thursday, February 25th, 2010

DeLand, Florida— February 25, 2010 — Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, Florida, announces the launch of several obesity and weight loss clinical trials to test investigational treatment options for those already diagnosed with obesity and weight loss problems. “We are very pleased to begin the systemic evaluation of our research studies to help find a viable investigational treatment solution to those suffering from obesity,” said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe that these research studies will build significantly on the data generated by other studies conducted on investigational treatment options for obesity and weight loss situations.” Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The research studies will enroll those already diagnosed with obesity, which includes symptoms like increased weight, increased body mass index, and other secondary complications. In order to participate in the studies volunteers must be diagnosed with obesity. Avail Clinical Research will not take volunteers who:

• have any evidence or treatment of malignancy within the previous 5 years,
• have a history of alcohol or substance abuse within the previous 5 years,
• have used an investigatory drug or participated in an investigatory study within 30 days of the screening,
• are pregnant, or
• are breast-feeding.

Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our clinical trials, contact Avail Clinical Research at 386.310.1334, or at www.AvailClinical.com.

Avail Clinical Research Announces Migraine Headaches Research Studies in DeLand, Florida

Wednesday, February 24th, 2010

DeLand, Florida— February 24, 2010 — Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, Florida, announces the launch of several migraine headaches clinical trials to test investigational treatment options for those already diagnosed with migraine headaches. “We are very pleased to begin the systemic evaluation of our research studies to help find a viable investigational treatment solution to those suffering from migraine headaches,” said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe that these research studies will build significantly on the data generated by other studies conducted on investigational treatment options for migraine headaches.” Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The research studies will enroll those already diagnosed with migraine headaches, which includes symptoms like moderate or severe pain on one side of the head, pulsing or throbbing headache, pain that worsens with physical activity, nausea without vomiting, and sensitivity to light and sound. In order to participate in the studies volunteers must be diagnosed with migraine headaches. Avail Clinical Research will not take volunteers who:

• have any evidence or treatment of malignancy within the previous 5 years,
• have a history of alcohol or substance abuse within the previous 5 years,
• have used an investigatory drug or participated in an investigatory study within 30 days of the screening,
• are pregnant, or
• are breast-feeding.

Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our clinical trials, contact Avail Clinical Research at 386.310.1334, or at www.AvailClinical.com.